Next 10 |
2024-11-13 17:27:57 ET More on Biofrontera Seeking Alpha’s Quant Rating on Biofrontera Historical earnings data for Biofrontera Financial information for Biofrontera Read the full article on Seeking Alpha For further details see: Biofronter...
WOBURN, Mass., Nov. 13, 2024 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI) (“Biofrontera” or the “Company”) , a biopharmaceutical company specializing in the development and commercialization of photodynamic therapy (PDT), today reported financial results for t...
Collective Audience Inc. (CAUD) is expected to report for Q3 2024 Cyanotech Corporation (CYAN) is expected to report for Q2 2025 CareRx Corporation (CHHHF) is expected to report $0 for Q3 2024 Boxlight Corporation (BOXL) is expected to report $-0.09 for Q3 2024 Biofrontera Inc. (B...
WOBURN, MA / ACCESSWIRE / November 1, 2024 / Biofrontera Inc. (Nasdaq:BFRI) ("Biofrontera" or the "Company") , a biopharmaceutical company specializing in the development and commercialization of PDT, announces it will report financial results for the three and nine months ended September 30, 202...
A look at the top 10 most actives in the United States NVIDIA Corporation (NVDA) fell 4.7% to $132.76 on volume of 265,013,220 shares LuxUrban Hotels Inc. (LUXH) rose 13.8% to $0.0404 on volume of 225,538,238 shares PROSHARES TRUST (SQQQ) rose 7.6% to $7.6 on volume of 209,287,865 shares ...
First Phase 3 PDT study in patients with sBCC in the United States. Primary and secondary endpoints all highly statistically significant p<0.0001 Correlates to data seen in Europe where sBCC is already incorporated in the Summary of Product Characteristics. BCC is the most common s...
First Phase 3 PDT study in patients with sBCC in the United States. Rigorous dual endpoints requiring complete clinical and cytological clearance of malignant lesions. Data now being analyzed, interim results expected November 2024. BCC is the most common skin cancer in the US with mo...
Approval allows for larger field treatment of actinic keratosis (AK) on face and scalp with Ameluz ® -PDT using the BF-RhodoLED or the RhodoLED XL lamp Supplemental New Drug Application (sNDA) supported by two Phase 1 safety studies AK is the second most common diagnosis made by ...
WOBURN, MA / ACCESSWIRE / September 25, 2024 / Biofrontera Inc. (NASDAQ:BFRI), a biopharmaceutical company specializing in the commercialization of dermatologic products, today announced that management will present at the 3rd Annual ROTH Healthcare Opportunities Conference to be held at the Met...
2024-08-15 13:34:14 ET Biofrontera Inc. (BFRI) Q2 2024 Earnings Conference Call August 15, 2024, 10:00 AM ET Company Participants Andrew Barwicki - Barwicki Investor Relations Hermann Luebbert - CEO, Chairman and Founder Fred Leffler - CFO Conference Call P...
News, Short Squeeze, Breakout and More Instantly...
WOBURN, Mass., Nov. 13, 2024 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI) (“Biofrontera” or the “Company”) , a biopharmaceutical company specializing in the development and commercialization of photodynamic therapy (PDT), today reported financial results for t...
Collective Audience Inc. (CAUD) is expected to report for Q3 2024 Cyanotech Corporation (CYAN) is expected to report for Q2 2025 CareRx Corporation (CHHHF) is expected to report $0 for Q3 2024 Boxlight Corporation (BOXL) is expected to report $-0.09 for Q3 2024 Biofrontera Inc. (B...
WOBURN, MA / ACCESSWIRE / November 1, 2024 / Biofrontera Inc. (Nasdaq:BFRI) ("Biofrontera" or the "Company") , a biopharmaceutical company specializing in the development and commercialization of PDT, announces it will report financial results for the three and nine months ended September 30, 202...